Article
Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.
International journal of medical sciences - 1 Jan 2016
Kanda Tatsuo, Yasui Shin, Nakamura Masato, Suzuki Eiichiro, Arai Makoto, Haga Yuki, Sasaki Reina, Wu Shuang, Nakamoto Shingo, Imazeki Fumio, Yokosuka Osamu
Abstract excerpt
Background. All-oral combination of direct-acting antivirals could lead to higher sustained virologic response (SVR) in hepatitis C virus (HCV)-infected patients. In the present study, we examined the efficacy and safety of the dual oral treatment with HCV nonstructural protein (NS) 5A inhibitor daclatasvir (DCV) plus HCV NS3/4A inhibitor asunaprevir (ASV) for 24 weeks in real-world HCV genotype 1-infected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.